Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure

Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure

Inhibition of sodium‐glucose cotransporter 2 (SGLT2) represents an emerging pharmaceutical approach for the treatment of heart failure. The mechanisms by which SGLT2 inhibitors reduce the risk of heart failure are not well understood. The objective of this study was to investigate the association be...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacology and therapeutics 2021-07, Vol.110 (1), p.149-158
Hauptverfasser: Katzmann, Julius L., Mason, Amy M., März, Winfried, Kleber, Marcus E., Niessner, Alexander, Blüher, Matthias, Speer, Thimoteus, Laufs, Ulrich
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 158
container_issue 1
container_start_page 149
container_title Clinical pharmacology and therapeutics
container_volume 110
creator Katzmann, Julius L.
Mason, Amy M.
März, Winfried
Kleber, Marcus E.
Niessner, Alexander
Blüher, Matthias
Speer, Thimoteus
Laufs, Ulrich
description Inhibition of sodium‐glucose cotransporter 2 (SGLT2) represents an emerging pharmaceutical approach for the treatment of heart failure. The mechanisms by which SGLT2 inhibitors reduce the risk of heart failure are not well understood. The objective of this study was to investigate the association between single nucleotide polymorphisms (SNPs) in the SLC5A2 gene, encoding SGLT2, and heart failure, and to assess potential mediators of this association. Regression and mediation analyses were conducted with individual participant data of the UK Biobank (n = 416,737) and validated in the cardiovascular high‐risk cohort of the LUdwigshafen RIsk and Cardiovascular Health study (LURIC; n = 3316). Two intronic SNPs associated with SLC5A2 expression were included in a genetic score, which was associated with lower risk of heart failure in UK Biobank (odds ratio 0.97, 95% confidence interval, 0.95−0.99, P = 0.016). This association was also present in participants without type 2 diabetes or coronary artery disease (CAD). The associations of the genetic score with HbA1c, high‐density lipoprotein cholesterol, uric acid, systolic blood pressure, waist circumference, and body composition mediated 35% of the effect of the score on heart failure risk. No associations of the genetic SGLT2 score with atherosclerotic cardiovascular disease outcomes or markers of volume status were observed, which was confirmed in the LURIC study. Variations in the gene encoding SGLT2 were associated with the risk of prevalent or incident heart failure. This association was mediated by several mechanisms and did not depend on the presence of type 2 diabetes or previous CAD events.
doi_str_mv 10.1002/cpt.2153
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2475533273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475533273</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3553-c2d9c2b79eb42acae7ba2d844187fa0ee0ed4c92936c1dfc22129410f597a6af3</originalsourceid><addsrcrecordid>eNp1kMtKw0AUQAdRbK2CXyCzdJM6rzxmKcW2QkHB6naYTG5kJMnEmQTpzk_wG_0SU1t15eZeLhzOhYPQOSVTSgi7Mm03ZTTmB2g8TBYlMY8P0ZgQIiPJeDJCJyG8DKeQWXaMRpwLEjOejdFiAQ101uAn7a3urGuwbfCDK2xff75_PFe9cQHwzHVeN6F1vgOPGdZNgZegfYfn2la9h1N0VOoqwNl-T9Dj_GY9W0aru8Xt7HoVGR7HPDKskIblqYRcMG00pLlmRSYEzdJSEwAChTCSSZ4YWpSGMcqkoKSMZaoTXfIJutx5W-9eewidqm0wUFW6AdcHxUQ6_OEs5X-o8S4ED6Vqva213yhK1DabGrKpbbYBvdhb-7yG4hf86TQA0Q54sxVs_hWp2f36W_gF90d29A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2475533273</pqid></control><display><type>article</type><title>Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure</title><source>Access via Wiley Online Library</source><creator>Katzmann, Julius L. ; Mason, Amy M. ; März, Winfried ; Kleber, Marcus E. ; Niessner, Alexander ; Blüher, Matthias ; Speer, Thimoteus ; Laufs, Ulrich</creator><creatorcontrib>Katzmann, Julius L. ; Mason, Amy M. ; März, Winfried ; Kleber, Marcus E. ; Niessner, Alexander ; Blüher, Matthias ; Speer, Thimoteus ; Laufs, Ulrich</creatorcontrib><description>Inhibition of sodium‐glucose cotransporter 2 (SGLT2) represents an emerging pharmaceutical approach for the treatment of heart failure. The mechanisms by which SGLT2 inhibitors reduce the risk of heart failure are not well understood. The objective of this study was to investigate the association between single nucleotide polymorphisms (SNPs) in the SLC5A2 gene, encoding SGLT2, and heart failure, and to assess potential mediators of this association. Regression and mediation analyses were conducted with individual participant data of the UK Biobank (n = 416,737) and validated in the cardiovascular high‐risk cohort of the LUdwigshafen RIsk and Cardiovascular Health study (LURIC; n = 3316). Two intronic SNPs associated with SLC5A2 expression were included in a genetic score, which was associated with lower risk of heart failure in UK Biobank (odds ratio 0.97, 95% confidence interval, 0.95−0.99, P = 0.016). This association was also present in participants without type 2 diabetes or coronary artery disease (CAD). The associations of the genetic score with HbA1c, high‐density lipoprotein cholesterol, uric acid, systolic blood pressure, waist circumference, and body composition mediated 35% of the effect of the score on heart failure risk. No associations of the genetic SGLT2 score with atherosclerotic cardiovascular disease outcomes or markers of volume status were observed, which was confirmed in the LURIC study. Variations in the gene encoding SGLT2 were associated with the risk of prevalent or incident heart failure. This association was mediated by several mechanisms and did not depend on the presence of type 2 diabetes or previous CAD events.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.2153</identifier><identifier>PMID: 33405238</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical pharmacology and therapeutics, 2021-07, Vol.110 (1), p.149-158</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics</rights><rights>2021 The Authors. Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3553-c2d9c2b79eb42acae7ba2d844187fa0ee0ed4c92936c1dfc22129410f597a6af3</citedby><cites>FETCH-LOGICAL-c3553-c2d9c2b79eb42acae7ba2d844187fa0ee0ed4c92936c1dfc22129410f597a6af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.2153$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.2153$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33405238$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katzmann, Julius L.</creatorcontrib><creatorcontrib>Mason, Amy M.</creatorcontrib><creatorcontrib>März, Winfried</creatorcontrib><creatorcontrib>Kleber, Marcus E.</creatorcontrib><creatorcontrib>Niessner, Alexander</creatorcontrib><creatorcontrib>Blüher, Matthias</creatorcontrib><creatorcontrib>Speer, Thimoteus</creatorcontrib><creatorcontrib>Laufs, Ulrich</creatorcontrib><title>Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Inhibition of sodium‐glucose cotransporter 2 (SGLT2) represents an emerging pharmaceutical approach for the treatment of heart failure. The mechanisms by which SGLT2 inhibitors reduce the risk of heart failure are not well understood. The objective of this study was to investigate the association between single nucleotide polymorphisms (SNPs) in the SLC5A2 gene, encoding SGLT2, and heart failure, and to assess potential mediators of this association. Regression and mediation analyses were conducted with individual participant data of the UK Biobank (n = 416,737) and validated in the cardiovascular high‐risk cohort of the LUdwigshafen RIsk and Cardiovascular Health study (LURIC; n = 3316). Two intronic SNPs associated with SLC5A2 expression were included in a genetic score, which was associated with lower risk of heart failure in UK Biobank (odds ratio 0.97, 95% confidence interval, 0.95−0.99, P = 0.016). This association was also present in participants without type 2 diabetes or coronary artery disease (CAD). The associations of the genetic score with HbA1c, high‐density lipoprotein cholesterol, uric acid, systolic blood pressure, waist circumference, and body composition mediated 35% of the effect of the score on heart failure risk. No associations of the genetic SGLT2 score with atherosclerotic cardiovascular disease outcomes or markers of volume status were observed, which was confirmed in the LURIC study. Variations in the gene encoding SGLT2 were associated with the risk of prevalent or incident heart failure. This association was mediated by several mechanisms and did not depend on the presence of type 2 diabetes or previous CAD events.</description><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kMtKw0AUQAdRbK2CXyCzdJM6rzxmKcW2QkHB6naYTG5kJMnEmQTpzk_wG_0SU1t15eZeLhzOhYPQOSVTSgi7Mm03ZTTmB2g8TBYlMY8P0ZgQIiPJeDJCJyG8DKeQWXaMRpwLEjOejdFiAQ101uAn7a3urGuwbfCDK2xff75_PFe9cQHwzHVeN6F1vgOPGdZNgZegfYfn2la9h1N0VOoqwNl-T9Dj_GY9W0aru8Xt7HoVGR7HPDKskIblqYRcMG00pLlmRSYEzdJSEwAChTCSSZ4YWpSGMcqkoKSMZaoTXfIJutx5W-9eewidqm0wUFW6AdcHxUQ6_OEs5X-o8S4ED6Vqva213yhK1DabGrKpbbYBvdhb-7yG4hf86TQA0Q54sxVs_hWp2f36W_gF90d29A</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Katzmann, Julius L.</creator><creator>Mason, Amy M.</creator><creator>März, Winfried</creator><creator>Kleber, Marcus E.</creator><creator>Niessner, Alexander</creator><creator>Blüher, Matthias</creator><creator>Speer, Thimoteus</creator><creator>Laufs, Ulrich</creator><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202107</creationdate><title>Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure</title><author>Katzmann, Julius L. ; Mason, Amy M. ; März, Winfried ; Kleber, Marcus E. ; Niessner, Alexander ; Blüher, Matthias ; Speer, Thimoteus ; Laufs, Ulrich</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3553-c2d9c2b79eb42acae7ba2d844187fa0ee0ed4c92936c1dfc22129410f597a6af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katzmann, Julius L.</creatorcontrib><creatorcontrib>Mason, Amy M.</creatorcontrib><creatorcontrib>März, Winfried</creatorcontrib><creatorcontrib>Kleber, Marcus E.</creatorcontrib><creatorcontrib>Niessner, Alexander</creatorcontrib><creatorcontrib>Blüher, Matthias</creatorcontrib><creatorcontrib>Speer, Thimoteus</creatorcontrib><creatorcontrib>Laufs, Ulrich</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katzmann, Julius L.</au><au>Mason, Amy M.</au><au>März, Winfried</au><au>Kleber, Marcus E.</au><au>Niessner, Alexander</au><au>Blüher, Matthias</au><au>Speer, Thimoteus</au><au>Laufs, Ulrich</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2021-07</date><risdate>2021</risdate><volume>110</volume><issue>1</issue><spage>149</spage><epage>158</epage><pages>149-158</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>Inhibition of sodium‐glucose cotransporter 2 (SGLT2) represents an emerging pharmaceutical approach for the treatment of heart failure. The mechanisms by which SGLT2 inhibitors reduce the risk of heart failure are not well understood. The objective of this study was to investigate the association between single nucleotide polymorphisms (SNPs) in the SLC5A2 gene, encoding SGLT2, and heart failure, and to assess potential mediators of this association. Regression and mediation analyses were conducted with individual participant data of the UK Biobank (n = 416,737) and validated in the cardiovascular high‐risk cohort of the LUdwigshafen RIsk and Cardiovascular Health study (LURIC; n = 3316). Two intronic SNPs associated with SLC5A2 expression were included in a genetic score, which was associated with lower risk of heart failure in UK Biobank (odds ratio 0.97, 95% confidence interval, 0.95−0.99, P = 0.016). This association was also present in participants without type 2 diabetes or coronary artery disease (CAD). The associations of the genetic score with HbA1c, high‐density lipoprotein cholesterol, uric acid, systolic blood pressure, waist circumference, and body composition mediated 35% of the effect of the score on heart failure risk. No associations of the genetic SGLT2 score with atherosclerotic cardiovascular disease outcomes or markers of volume status were observed, which was confirmed in the LURIC study. Variations in the gene encoding SGLT2 were associated with the risk of prevalent or incident heart failure. This association was mediated by several mechanisms and did not depend on the presence of type 2 diabetes or previous CAD events.</abstract><cop>United States</cop><pmid>33405238</pmid><doi>10.1002/cpt.2153</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-9236
ispartof Clinical pharmacology and therapeutics, 2021-07, Vol.110 (1), p.149-158
issn 0009-9236
1532-6535
language eng
recordid cdi_proquest_miscellaneous_2475533273
source Access via Wiley Online Library
title Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T00%3A55%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20Variation%20in%20Sodium%E2%80%90glucose%20Cotransporter%202%20and%20Heart%20Failure&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Katzmann,%20Julius%20L.&rft.date=2021-07&rft.volume=110&rft.issue=1&rft.spage=149&rft.epage=158&rft.pages=149-158&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.2153&rft_dat=%3Cproquest_cross%3E2475533273%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2475533273&rft_id=info:pmid/33405238&rfr_iscdi=true